TRiCBIO PDO 2.0 studies in clear-cell renal cell carcinoma (ccRCC) and non-small-cell lung cancer (NSCLC) combine tissue identity, immune baseline and treatment-response readouts to guide immuno-oncology study design.
STUDY AND RESULTS
Tissue baseline, immune stimulation and treatment-response readouts offer complementary views for tumor–immune studies.
View imageSource tissue and PDOs at days 7 and 28 show PanCK, CD3 and DAPI signals side by side for comparison of tumor-epithelial and sample-associated immune signals.
Provides baseline data for immune quantification and treatment studies
View imageTissue imaging under ±IL-2 conditions shows the response to stimulation and can be combined with subsequent flow and cytokine assays.
Informs dose, time-point and cytokine-endpoint selection
View imagePD-L1-, CD8- and CD56-associated flow profiles are interpreted alongside early-apoptosis and necrosis readouts to compare immune-associated and cell-death changes under ICB conditions.
Informs candidate and independent-sample comparisons
View imageIMAGING & FLOW ASSAYS
PanCK, CD3, DAPI and tissue morphology
Measurable tumor context and immune signals
Multi-field quantification, replication and sample-specific windows
CD3, PanCK and DAPI immunofluorescence
Interpretable change after immune stimulation
Dose/time, cytokine and gating analyses
PD-L1-, CD8- and CD56-associated flow profiles with apoptosis and necrosis
Relationship between immune change and cell-death readouts
Candidate mechanism, target context and independent-sample comparisons
Use immune-cell profiles and treatment responses to design the next candidate, dose and independent-sample study.
Sample baseline informs the culture window, flow-cytometry gating and replication design so immune and cell-death-related changes can be compared clearly across treatment conditions.
INTERPRETATION
Select histology, cell-death and T-cell profiling endpoints for immunotherapy studies across different sample contexts.
Programs select the observation window and assay panel from each sample's immune baseline and culture state, then extend the study through replication and additional samples.
Set dose, time, cytokine and flow analyses around the candidate mechanism, then compare responses across replicates and independent samples.
Related models and services
PROJECT DISCUSSION
Tell us which model, assay or finding you want to extend. Our scientists will adapt the approach to your candidate, samples and decision point.
TRiCBIO PDO 2.0 studies in clear-cell renal cell carcinoma (ccRCC) and non-small-cell lung cancer (NSCLC) combine tissue identity, immune baseline and treatment-response readouts to guide immuno-oncology study design.
STUDY AND RESULTS
Tissue baseline, immune stimulation and treatment-response readouts offer complementary views for tumor–immune studies.
View imageSource tissue and PDOs at days 7 and 28 show PanCK, CD3 and DAPI signals side by side for comparison of tumor-epithelial and sample-associated immune signals.
Provides baseline data for immune quantification and treatment studiesView imageTissue imaging under ±IL-2 conditions shows the response to stimulation and can be combined with subsequent flow and cytokine assays.
Informs dose, time-point and cytokine-endpoint selectionView imagePD-L1-, CD8- and CD56-associated flow profiles are interpreted alongside early-apoptosis and necrosis readouts to compare immune-associated and cell-death changes under ICB conditions.
Informs candidate and independent-sample comparisonsView imageIMAGING & FLOW ASSAYS
PanCK, CD3, DAPI and tissue morphology
Measurable tumor context and immune signals
Multi-field quantification, replication and sample-specific windows
CD3, PanCK and DAPI immunofluorescence
Interpretable change after immune stimulation
Dose/time, cytokine and gating analyses
PD-L1-, CD8- and CD56-associated flow profiles with apoptosis and necrosis
Relationship between immune change and cell-death readouts
Candidate mechanism, target context and independent-sample comparisons
Use immune-cell profiles and treatment responses to design the next candidate, dose and independent-sample study.
Sample baseline informs the culture window, flow-cytometry gating and replication design so immune and cell-death-related changes can be compared clearly across treatment conditions.
INTERPRETATION
Select histology, cell-death and T-cell profiling endpoints for immunotherapy studies across different sample contexts.
Programs select the observation window and assay panel from each sample's immune baseline and culture state, then extend the study through replication and additional samples.
Set dose, time, cytokine and flow analyses around the candidate mechanism, then compare responses across replicates and independent samples.
Related models and services
PROJECT DISCUSSION
Tell us which model, assay or finding you want to extend. Our scientists will adapt the approach to your candidate, samples and decision point.
